Lv11
26 积分 2023-09-27 加入
A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer
1小时前
已完结
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations
4小时前
已完结
A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer
6天前
已完结
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition
6天前
已完结
Pilocytic astrocytoma harboring a novel GNAI3‐BRAF fusion
7天前
已完结
Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway
1个月前
已完结
The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients
2个月前
已完结
[Characteristics of RET gene rearrangement detected by fluorescence in situ hybridization in lung cancer]
2个月前
已完结
Comparative analysis of somatic and germline polymerase proofreading deficiencies in cancer: molecular and clinical implications
3个月前
已关闭
皖公网安备34019202002308
